Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 701–800 of 2,327
Vilibić‐Čavlek, T., Stevanović, V., Ilić, M., Barbić, L., Capak, K., Tabain, I., Krleža, J. L., Ferenc, T., Hruškar, Ž., Topić, R. Z., et al. (2021) · Pathogens · doi:10.3390/pathogens10060774 · Cited by 25
Alonso, S., Álvarez-Lacalle, E., Català, M., López, D., Jordán, I., García‐García, J. J., Soriano‐Arandes, A., Lazcano, U., Sallés, P., Masats, M., et al. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003279 · Cited by 25
Babiker, A. Y. M., Immergluck, K., Stampfer, S. D., Rao, A., Bassit, L., Su, M., Nguyen, V., Stittleburg, V. D., Ingersoll, J., Bradley, H. L., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01446-21 · Cited by 29
Krafft, É., Denolly, S., Boson, B., Angelloz-Pessey, S., Levaltier, S., Nesi, N., Corbet, S., Leterrier, B., Fritz, M., Leroy, E. M., et al. (2021) · Viruses · doi:10.3390/v13091759 · Cited by 25
Patient Nutrition and Probiotic Therapy in COVID-19: What Do We Know in 2021?
Hawryłkowicz, V., Lietz–Kijak, D., Kaźmierczak-Siedlecka, K., Sołek-Pastuszka, J., Stachowska, L., Folwarski, M., Parczewski, M., & Stachowska, E. (2021) · Nutrients · doi:10.3390/nu13103385 · Cited by 26
“Prognostic models and initial epidemiological data show that new variants of SARS-CoV-2 are associated with higher transmissibility [2,3].”
BackgroundKhan, A., Hussain, S., Ahmad, S., Suleman, M., Bukhari, I., Khan, T., Rashid, F., Azad, A. K., Waseem, M., Khan, W., et al. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105163 · Cited by 26
New Variant of SARS‐CoV‐2 Dynamics with Imperfect Vaccine
Faniran, T. S., Ali, A., Al‐Hazmi, N. E., Asamoah, J. K. K., Nofal, T. A., & Adewole, M. O. (2022) · Complexity · doi:10.1155/2022/1062180 · Cited by 25
Pavan, M., Bassani, D., Sturlese, M., & Moro, S. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2081847 · Cited by 24
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
Wettstein, L., Knaff, P. M., Kersten, C., Müller, P., Weil, T., Conzelmann, C., Müller, J. A., Brückner, M., Hoffmann, M., Pöhlmann, S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03613-4 · Cited by 28
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 25
“…B.1.1.7 variant, called the alpha variant in WHO nomenclature, was first detected in September 2020 in the United Kingdom (Galloway, 2021), and by early 2021 had become the dominant variant causing new infections in the UK, before spreading worldwide (Davies et al., 2021; Washington et al., 2021).”
InfluentialVimalanathan, S., Shehata, M. M., Sadasivam, K., Delbue, S., Dolci, M., Pariani, E., D'Alessandro, S., & Pleschka, S. (2022) · Microorganisms · doi:10.3390/microorganisms10112145 · Cited by 12
“Notably, the strain exhibited a higher reproduction rate than pre-existing variants resulting in higher viral loads and longer infectious periods [9,10].”
Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 29
Paireau, J., Charpignon, M., Larrieu, S., Calba, C., Hozé, N., Boëlle, P., Thiébaut, R., Prague, M., & Cauchemez, S. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08106-1 · Cited by 25
Addetia, A., Park, Y., Starr, T. N., Greaney, A. J., Sprouse, K. R., Bowen, J. E., Tilles, S. W., Voorhis, W. C. V., Bloom, J. D., Corti, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112621 · Cited by 24
Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022
Solastie, A., Nieminen, T., Ekström, N., Nohynek, H., Lehtonen, L., Palmu, A., & Melin, M. (2023) · medRxiv · doi:10.1080/22221751.2023.2222849 · Cited by 20
“cine-induced immunity despite the emergence and dominance of more transmissible Alpha [26,27] and Delta variants [14,28,29].”
BackgroundFang, L., Xu, J., Zhao, Y., Fan, J., Shen, J., Liu, W., & Cao, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1228128 · Cited by 27
“It was proven to be highly transmissible and infectious, and became prevalent a few months later (Davies et al., 2021; Volz et al., 2021).”
BackgroundMathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission
Swan, D. A., Goyal, A., Bracis, C., Moore, M., Krantz, E. M., Brown, E. R., Ojeda, E. F. C., Reeves, D. B., Gao, F., Gilbert, P. B., et al. (2021) · Viruses · doi:10.3390/v13101921 · Cited by 27
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 31
Khedar, R. S., Mittal, K., Ambaliya, H. C., Mathur, A. V., Gupta, J. B., Sharma, K. K., Singh, Y., Sharma, G., Gupta, A., Bhargava, V., et al. (2021) · medRxiv · doi:10.1101/2021.09.03.21263091 · Cited by 25
Costacurta, F., Dodaro, A., Bante, D., Schöppe, H., Peng, J.-Y., Sprenger, B., He, X. C., Moghadasi, S. A., Egger, L. M., Fleischmann, J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012522 · Cited by 28
“As vaccines do not confer complete immunity against infection, the virus continues to spread effectively due to easier host-to-host transmission [2], and immune-escaping variants, such as Beta, Delta and Omicron [3–5].”
BackgroundZhao, S., Lou, J., Chong, K. C., Cao, L., Zheng, H., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · Viruses · doi:10.3390/v13040638 · Cited by 24
On the origin of SARS-CoV-2—The blind watchmaker argument
Wu, C., Wen, H., Lü, J., Su, X., Hughes, A. C., Zhai, W., Chen, C., Chen, H., Li, M., Song, S., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1972-1 · Cited by 21
“Indeed, in the SARS of 2003–2004 and in COVID-19, the power of natural selection has been amply demonstrated by the increasingly successful new strains (Davies et al., 2021; Korber et al., 2020; Tegally et al., 2020; Voloch et al., 2021) that evolve in humans.”
BackgroundSahajpal, N., Mondal, A. K., Njau, A. N., Petty, Z., Chen, J., Ananth, S., Ahluwalia, P. K., Williams, C., Ross, T. M., Chaubey, A., et al. (2021) · Viruses · doi:10.3390/v13102063 · Cited by 23
“The VOC 202012/01 SARS-CoV-2 strain was 43–90% more transmissible compared to the preexisting strains and led to “Tier 4” restrictions in December 2020 in the UK, and the delta variant is emerging as a similar threat [6].”
BackgroundBinding affinity and mechanisms of SARS-CoV-2 variants
Han, Y., Wang, Z., Wei, Z., Schapiro, I., & Li, J. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.026 · Cited by 25
Hogan, C. A., Jassem, A. N., Sbihi, H., Joffres, Y., Tyson, J. R., Noftall, K., Taylor, M., Lee, T., Fjell, C. D., Wilmer, A., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2711.211190 · Cited by 24
D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 24
Sunohara, S., Asakura, T., Kimura, T., Ozawa, S., Oshima, S., Yamauchi, D., & Tamakoshi, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257107 · Cited by 30
“However, a new SARS-CoV-2 variant, VOC 202012/01 was reported to be 43-90% higher transmissibility than preexisting variants [37,38] and has been appeared also in Japan.”
BackgroundPasquale, A. D., Radomski, N., Mangone, I., Calistri, P., Lorusso, A., & Cammà, C. (2021) · BMC Genomics · doi:10.1186/s12864-021-08112-0 · Cited by 28
“351 and P1 were first detected in United Kingdom (UK) [73], South Africa [74] and Brazil [75], respectively.”
BackgroundEx vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Becker, J., Stanifer, M. L., Leist, S. R., Stolp, B., Maiakovska, O., West, A., Wiedtke, E., Börner, K., Ghanem, A., Ambiel, I., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.024 · Cited by 25
Giardina, J., Bilinski, A., Fitzpatrick, M. C., Kendall, E. A., Linas, B. P., Salomon, J. A., & Ciaranello, A. L. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47827 · Cited by 24
Prüβ, B. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702065 · Cited by 28
“It is considered 43% to 82% more transmissible [65].”
BackgroundThe need for linked genomic surveillance of SARS-CoV-2
Dushoff, C., Earn, D. J. D., Dushoff, J. G., Ogden, N. H., Li, M., Knox, N., Domselaar, G. V., Franklin, K., Jolly, G., & Otto, S. P. (2022) · Canada Communicable Disease Report · doi:10.14745/ccdr.v48i04a03 · Cited by 28
Morales-Zamora, G., Espinosa, O., Puertas, E., Fernández, J. C., Hernández, J., Zakzuk, V., Cepeda, M., Alvis‐Guzmán, N., Castañeda-Orjuela, C. A., & Paternina-Caicedo, Á. J. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2022.04.004 · Cited by 24
Boytz, R., Slabicki, M. M., Ramaswamy, S., Patten, J. J., Zou, C., Meng, C., Hurst, B. L., Wang, J., Nowak, R. P., Yang, P. L., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28157 · Cited by 24
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
Chen, Z., Zhang, P., Matsuoka, Y., Tsybovsky, Y., West, K. A., Santos, C. P., Boyd, L. F., Nguyen, H., Pomerenke, A., Stephens, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111528 · Cited by 26
“…transmissibility or pathogenicity as well as resistance to monoclonal antibodies (mAbs) and vaccine-elicited antibodies (Corti et al., 2021; Davies et al., 2021; Wang et al., 2021; Wibmer et al., 2021), highlighting the need for effective therapeutic and preventive measures with a broad…”
Sustained seropositivity up to 20.5 months after COVID-19
Dobaño, C., Ramírez‐Morros, A., Alonso, S., Rubio, R., Ruiz‐Olalla, G., Vidal‐Alaball, J., Macià, D., Catalina, Q. M., Vidal, M., Fuster‐Casanovas, A., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02570-3 · Cited by 27
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 26
“Despite worries about the higher transmissibility compared to other circulating variants at the time [106,107], clinical studies demonstrated how mAbs, CP, and especially vaccines, were still able to confer protection against B.”
BackgroundIwamoto, R., Yamaguchi, K., Katayama, K., Ando, H., Setsukinai, K., Kobayashi, H., Okabe, S., Imoto, S., & Kitajima, M. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.163706 · Cited by 23
RetractedLythgoe, K., Golubchik, T., Hall, M. D., House, T., Cahuantzi, R., MacIntyre-Cockett, G., Fryer, H. R., Thomson, L., Nurtay, A., Ghafari, M., et al. (2023) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2023.1284 · Cited by 37
Impact of COVID-19 Vaccination: A Global Perspective
Singh, P., Anand, A., Rana, S., Kumar, A., Goel, P., Kumar, S., Gouda, K. C., & Singh, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1272961 · Cited by 25
“The B.1.1.7 (Alpha) variant has been linked with an increased risk of transmissibility, hospitalization, and death (8, 11–14).”
BackgroundInfluentialPredicting potential SARS-CoV-2 mutations of concern via full quantum mechanical modelling
Zaccaria, M., Genovese, L., Lawhorn, B. E., Dawson, W., Joyal, A. S., Hu, J., Autissier, P., Nakajima, T., Johnson, W. E., Fofana, I., et al. (2024) · Journal of The Royal Society Interface · doi:10.1098/rsif.2023.0614 · Cited by 21
Horspool, A. M., Ye, C., Wong, T. Y., Russ, B. P., Lee, K. S., Winters, M. T., Bevere, J. R., Kieffer, T. W., Martínez, I., Sourimant, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.05.442784 · Cited by 22
Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21
Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data
Lee, B., Quadeer, A. A., Sohail, M. S., Finney, E., Ahmed, S. F., McKay, M. R., & Barton, J. P. (2025) · Nature Communications · doi:10.1038/s41467-024-55593-0 · Cited by 44
Di, A., Cunha, F., Petrosillo, N., Beeching, N. J., Ergonul, O., Petersen, E., & Koopmans, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.03.011 · Cited by 26
A comparison of persistence of SARS-CoV-2 variants on stainless steel
Pottage, T., Garratt, I., Onianwa, O., Spencer, A., Paton, S., Verlander, N. Q., Dunning, J. W., & Bennett, A. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.05.015 · Cited by 23
Morris, C. P., Luo, C. H., Amadi, A., Schwartz, M. C., Gallagher, N., Ray, S. C., Pekosz, A. S., & Mostafa, H. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab636 · Cited by 28
Ladhani, S. N., Ireland, G., Baawuah, F., Beckmann, J., Okike, I. O., Ahmad, S. S. Y., Garstang, J. J., Brent, A., Brent, B., Aiano, F., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.08.019 · Cited by 24
Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection
Serpeloni, J. M., Neto, Q. A. D. L., Lúcio, L. C., Ramão, A., de Oliveira, J. C., Gradia, D. F., Malheiros, D., Ferrasa, A., Marchi, R., Figueiredo, D. L. A., et al. (2021) · Immunobiology · doi:10.1016/j.imbio.2021.152130 · Cited by 25
Kuo, C., Yang, T., Chien, Y.-C., Yu, P., Hsu, S. D., & Khoo, K. (2021) · Glycobiology · doi:10.1093/glycob/cwab102 · Cited by 24
Egeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Joseph‐McCarthy, D., & Chakravarty, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-02148-8 · Cited by 25
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Ashcroft, P., Lehtinen, S., & Bonhoeffer, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263597 · Cited by 29
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
Chi, X., Guo, Y., Zhang, G., Sun, H., Zhang, J., Li, M., Chen, Z., Han, J., Zhang, Y., Zhang, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00987-z · Cited by 21
Agent-based simulations for protecting nursing homes with prevention and vaccination strategies
Lasser, J., Zuber, J. A., Sorger, J., Dervić, E., Ledebur, K., Lindner, S. D., Klager, E., Kletečka-Pulker, M., Willschke, H., Stangl, K., et al. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0608 · Cited by 24
Mutation induced infection waves in diseases like COVID-19
Schwarzendahl, F. J., Grauer, J., Liebchen, B., & Löwen, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-13137-w · Cited by 24
Transmission of SARS-CoV-2 among children and staff in German daycare centres
Loss, J., Wurm, J., Varnaccia, G., Schienkiewitz, A., Iwanowski, H., Loer, A.-K. M., Allen, J., Wess, B., Rosario, A. S., Damerow, S., et al. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822001194 · Cited by 23
“Increased transmissibility was postulated with the advent of SARS-CoV-2 ‘variants of concern’ (VOC), such as the Alpha or Delta variant [8, 9], although its role in outbreaks in daycare centres remains unknown.”
BackgroundGe, J., Digitale, J. C., Pletcher, M. J., & Lai, J. C. (2022) · Hepatology · doi:10.1002/hep.32780 · Cited by 23
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 28
“7) 69‐70del, 144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H United Kingdom, Sep‐2020 Approximately 50% increased transmission.(29,30) No impact on susceptibility to EUA mAb treatments.”
BackgroundBarghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 27
“…mutations [52], including critical changes in the spike protein, Alpha demonstrated significantly higher transmissibility than earlier variants [53,54]. stability, and resistance to authorized monoclonal antibodies, the Omicron variant poses new challenges to global efforts in combating…”
COVID-19 vaccines in patients with cancer
Trapani, D., & Curigliano, G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00250-3 · Cited by 22
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
Trinité, B., Pradenas, E., Marfil, S., Rovirosa, C., Urrea, V., Tarrés-Freixas, F., Ortiz, R., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2021) · Viruses · doi:10.3390/v13061135 · Cited by 20
“7 is associated with a higher hospitalization risk [3] and higher mortality [4] and several reports indicate that it has a higher secondary attack rate, making this viral variant 30–50% more transmissible [5].”
BackgroundComparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 Isolates
Moustafa, A. M., Bianco, C. M., Denu, L., Ahmed, A., Coffin, S. E., Neide, B., Everett, J. K., Reddy, S. G., Rabut, E., Deseignora, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab300 · Cited by 24
“applyparastyle “fig//caption/p[1]” parastyle “FigCapt””
Baum, U., Poukka, E., PALMU, A. A. I., Salo, H., Lehtonen, T., & Leino, T. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258704 · Cited by 21
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
Mumtaz, G. R., El‐Jardali, F., Jabbour, M., Harb, A., Abu-Raddad, L. J., & Makhoul, M. (2021) · Vaccines · doi:10.3390/vaccines9070697 · Cited by 25
“As restrictions were gradually eased starting 15 April 2021, R0 was gradually increased to reach R0=6 at the end of the four months, thus accounting for the increased transmissibility in absence of non-therapeutic interventions of the new SARS-CoV-2 variants of concern [15, 27-31].”
BackgroundDennis, J., McGovern, A. P., Thomas, N. J., Wilde, H., Vollmer, S. J., & Mateen, B. A. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005184 · Cited by 22
Breidenbach, P., & Mitze, T. (2021) · Econometrics Journal · doi:10.1093/ectj/utab021 · Cited by 26
Mok, B. W.-Y., Liu, H., Deng, S., Liu, J., Zhang, J., Lau, S.-Y., Liu, S., Tam, R. C.-Y., Cremin, C. J., Ng, T. T.-L., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02640-x · Cited by 25
Erster, O., Mendelson, E., Levy, V., Kabat, A., Mannasse, B., Asraf, H., Azar, R., Ali, Y., Shirazi, R., Bucris, E. D., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00506-21 · Cited by 22
EpiBeds: Data informed modelling of the COVID-19 hospital burden in England
Overton, C. E., Pellis, L., Stage, H. B., Scarabel, F., Burton, J., Fraser, C., Hall, I., House, T., Jewell, C., Nurtay, A., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010406 · Cited by 20
Monel, B., Planas, D., Grzelak, L., Smith, N., Robillard, N., Staropoli, I., Gonçalves, P., Porrot, F., Guivel‐Benhassine, F., Guinet, N. D., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103637 · Cited by 23
“Other studies did not indicate a clear clinical effect associated with alpha infection [2,46,47] or showed that it is important to take into account morbidities during winter months [11].”
A metagenomics workflow for SARS-CoV-2 identification, co-pathogen detection, and overall diversity
Castañeda-Mogollón, D., Kamaliddin, C., Oberding, L. K., Liu, Y., Mohon, A. N., Faridi, R. M., Khan, F. M., & Pillai, D. R. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105025 · Cited by 25
Munch, P. K., Espenhain, L., Hansen, C. H., Müller, L., Krause, T. G., & Ethelberg, S. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002478 · Cited by 26
de Souza, G. A. P., Bideau, M. L., Boschi, C., Ferreira, L., Wurtz, N., Devaux, C. A., Colson, P., & Scola, B. L. (2021) · Viruses · doi:10.3390/v14010023 · Cited by 22
“This new variant was attributed to an increased transmission rate of around 50% [19] and a minimal difference in neutralisation by convalescent and post-vaccination sera [11,13,48].”
BackgroundComparative characterization of SARS‐CoV‐2 variants of concern and mouse‐adapted strains in mice
Chen, Q., Huang, X., Liu, Y., Sun, M., Ji, B., Chao Hui, Z. H. O. U., Chi, H., Zhang, R., Luo, D., Tian, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27735 · Cited by 21
SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant
Meyerowitz, E. A., & Richterman, A. G. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.007 · Cited by 37
“It was defined by 17 mutations, including 8 in the spike protein, and it rapidly became dominant in the UK and much of the world, with researchers estimating it was 43% to 90%more transmissible than its predecessor virus.(14) A Japanese study found that the secondary attack rate in households was significantly higher…”
Iaconis, D., Bordi, L., Matusali, G., Talarico, C., Manelfi, C., Cesta, M. C., Zippoli, M., Caccuri, F., Bugatti, A., Zani, A., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04961-z · Cited by 21
Xiong, D., Zhao, X., Luo, S., Cong, Y., Zhang, J. Z. H., & Duan, L. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c00912 · Cited by 24
Collin, A., Hejblum, B. P., Vignals, C., Lehot, L., Thiébaut, R., Moireau, P., & Prague, M. (2023) · The International Journal of Biostatistics · doi:10.1515/ijb-2022-0087 · Cited by 31
SARS-CoV-2 infection and immune responses
Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 24
Wohl, S., Lee, E. C., DiPrete, B. L., & Lessler, J. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101022 · Cited by 26
“1 per day.(18) Now, we can use Equation 7 to calculate the per-day sample size needed to ensure detection (with 95% probability) of this Alphalike variant within 30 days of its initial emergence:”
MethodChandrashekar, A., Liu, J., Yu, J., McMahan, K., Tostanoski, L. H., Jacob-Dolan, C., Mercado, N. B., Anioke, T., Chang, A., Gardner, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2641 · Cited by 23
Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves
Swann, O. V., Pollock, L., Holden, K. A., Munro, A. P. S., Bennett, A., Williams, T. C., Turtle, L. C. W., Fairfield, C. J., Drake, T. M., Faust, S. N., et al. (2022) · Pediatric Research · doi:10.1038/s41390-022-02052-5 · Cited by 22
“This may have been due to the emergence of the variant coinciding with a period when schools were open and subject to increased testing, but the rest of UK society was in “lockdown”.(12) Whether the alpha variant, dominant in the second wave, causes different symptoms or more severe disease in CYP compared to strains…”
BackgroundStarr, T. N., Czudnochowski, N., Zatta, F., Park, Y., Liu, Z., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.06.438709 · Cited by 24
Richard, D., Shaw, L. P., Lanfear, R., Corbett-Detig, R. B., Hinrichs, A. S., McBroome, J., Turakhia, Y., Acman, M., Owen, C. J., Tan, C. C. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.442903 · Cited by 21
Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivityPreprint
Yao, W., Ma, D., Wang, H., Tang, X., Du, C., Pan, H., Li, C., Lin, H., Farzan, M., Zhao, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.27.428353 · Cited by 22
Yuan, S.-F., Ye, Z.-W., Liang, R., Tang, K., Zhang, A., Lu, G., Ong, C., Poon, V., Chan, C., Mok, B.-B. W., et al. (2022) · bioRxiv · doi:10.1101/2022.01.12.476031 · Cited by 26
Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
Yajima, H., Nomai, T., Okumura, K., Maenaka, K., Ito, J., Hashiguchi, T., Sato, K., Matsuno, K., Nao, N., Sawa, H., et al. (2024) · mBio · doi:10.1128/mbio.03220-23 · Cited by 33
Chen, Y., Zhu, L., Huang, W., Tong, X., Wu, H., Tao, Y., Tong, B., Huang, H., Chen, J., Zhao, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1942227 · Cited by 20
“convalescent individuals and vaccine recipients [5, 6].”
Application of omics technology to combat the COVID‐19 pandemic
Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 21
Sideward contact tracing and the control of epidemics in large gatherings
Mancastroppa, M., Guizzo, A., Castellano, C., Vezzani, A., & Burioni, R. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0048 · Cited by 21
Antibody cocktail effective against variants of SARS-CoV-2
Liang, K.-H., Chiang, P.-Y., Ko, S.-H., Chou, Y., Lu, R., Lin, H.-T., Wy, C., Lin, Y., Tao, M., Jan, J., et al. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00777-9 · Cited by 20
Wang, Y., Zhang, F., Byrd, J. B., Yu, H. J., Ye, X., & He, Y. O. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.770031 · Cited by 23
Donnelly, M. A. P., Chuey, M. R., Soto, R. A., Schwartz, N. G., Chu, V. T., Konkle, S. L., Sleweon, S., Ruffin, J. D., Haberling, D. L., Guagliardo, S. A. J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac125 · Cited by 22
Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?
Tran, B. M., Deliyannis, G., Hachani, A., Earnest, L., Torresi, J., & Vincan, E. (2022) · Organoids · doi:10.3390/organoids1010002 · Cited by 22
Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 23
“There is evidence that N501Y causes up to 56% higher transmissibility in individuals [55].”
BackgroundFerreira, L. S., Canton, O., Lopes, R., Poloni, S., Sudbrack, V., Borges, M. E., Franco, C. F. J., Marquitti, F. M. D., de Moraes, J. C., Veras, M. A. D. S. M., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009978 · Cited by 21
“4, accounting for potentially more transmissible variants [19, 22] or increased contact rates due to less rigid non-pharmaceutical interventions.”
BackgroundCOVID-19 Genetic Variants and Their Potential Impact in Vaccine Development
Giau, V. V., Bagyinszky, E., & An, S. S. A. (2022) · Microorganisms · doi:10.3390/microorganisms10030598 · Cited by 21
Parker, M. D., Stewart, H., Shehata, O. M., Lindsey, B. B., Shah, D. R., Hsu, S. N., Keeley, A. J., Partridge, D. G., Leary, S., Cope, A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03565-9 · Cited by 52
Ekroth, A. K. E., Patrzylas, P., Turner, C., Hughes, G. J., & Anderson, C. S. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822001297 · Cited by 21
“The emergence of the Alpha variant in September 2020 [1] was associated with a 43–90% increase in observed transmission compared to the original wildtype strain [2].”
Background
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.